Boosting Glioblastoma Therapy with Targeted Pyroptosis Induction
Small · 2023-07 · 19 (30)
DOI: 10.1002/smll.202207604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 17.04.2023. Verfasst von Xinggang Fang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical College of Traditional Chinese Medicine, Taihe Hospital, Hubei University of Chinese Medicine, Wuhan, Hubei, 430065, P. R. China. Hauptthemen laut MEDLINE: Glioblastoma, Nanoparticles, Brain Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive cancer that currently lacks effective treatments. Pyroptosis has emerged as a promising therapeutic approach for cancer, but there is still a need for new pyroptosis boosters to target cancer cells. In this study, it is reported that Aloe‐emodin (AE), a natural compound derived from plants, can inhibit GBM cells by inducing pyroptosis, making it a potential booster for pyroptosis‐mediated GBM therapy. However, administering AE is challenging due to the blood‐brain barrier (BBB) and its non‐selectivity. To overcome this obstacle, AE@ZIF‐8 NPs are developed, a biomineralized nanocarrier that releases AE in response to the tumor's acidic microenvironment (TAM). Further modification of the nanocarrier with transferrin (Tf) and polyethylene glycol‐poly (lactic‐co‐glycolic acid) (PEG‐PLGA) improves its penetration through the BBB and tumor targeting, respectively. The results show that AE‐NPs (Tf‐PEG‐PLGA modified AE@ZIF‐8 NPs) significantly increase the intracranial distribution and tumor tissue accumulation, enhancing GBM pyroptosis. Additionally, AE‐NPs activate antitumor immunity and reduce AE‐related toxicity. Overall, this study provides a new approach for GBM therapy and offers a nanocarrier that is capable of penetrating the BBB, targeting tumors, and attenuating toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical College of Traditional Chinese Medicine, Taihe Hospital, Hubei University of Chinese Medicine, Wuhan, Hubei, 430065, P. R. China.
- Department of Neurosurgery, Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan, H…
- Department of Integrated Chinese and Western Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, P. R. China.
- Pharmaceutical Sciences Laboratory, Åbo Akademi University, 20520, Turku, Finland.
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland.
- School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei, 442000, P. R. China.
ORCID-Profile: Hongbo Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fang, X., Chen, Z., Zhou, W., Li, T., Wang, M., Gao, Y., Ma, S., Feng, Y., Du, S., Lan, P., Chen, H., Wei, J., Zhang, S., Li, Z., Liu, X., Zhang, H., Guo, X., & Luo, J. (2023). Boosting Glioblastoma Therapy with Targeted Pyroptosis Induction. Small, 19(30). https://doi.org/10.1002/smll.202207604
Vancouver
Fang X, Chen Z, Zhou W, Li T, Wang M, Gao Y, et al. Boosting Glioblastoma Therapy with Targeted Pyroptosis Induction. Small. 2023;19(30). doi:10.1002/smll.202207604
BibTeX
@article{Fang2023,
author = {Fang, Xinggang and Chen, Zhuo and Zhou, Wenhui and Li, Tongfei and Wang, Man and Gao, Yujiu and Ma, Shinan and Feng, Ying and Du, Shiming and Lan, Peimin and Chen, Hanyu and Wei, Jiarui and Zhang, Sisi and Li, Zixiang and Liu, Xinglin and Zhang, Hongbo and Guo, Xingrong and Luo, Jie},
title = {Boosting Glioblastoma Therapy with Targeted Pyroptosis Induction},
journal = {Small},
year = {2023},
volume = {19},
number = {30},
doi = {10.1002/smll.202207604}
}
EUVIMED